Duck medicine and vaccines market

Q: Which is the leading application segment in the market?

Farm is the leading application segment in the market. Read more

Duck Medicine and Vaccines Market, by Type (Medicine and Vaccines), by Application (Farm and Government), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Request Free Sample

Mar 2022
CMI4956
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Ducks are relatively resistant to disease, but they have been known to carry diseases that are infectious to other types of poultry. However, some of the common diseases in ducks include duck virus hepatitis, duck plague, pasteurellosis, and aflatoxicosis. As there is no treatment for many of these diseases, such as duck plague, duck hepatitis, and others, vaccinating the ducks is essential to prevent such diseases. Also, providing proper housing, management, ventilation, and nutrition to ducks can make them less susceptible to diseases.

The global duck medicine and vaccines market is estimated to be valued at US$ 1,777.0 million in 2021 and is expected to exhibit a CAGR of 7.7% during the forecast period (2021-2028).

Figure 1. Global Duck Medicine and Vaccines Market Share (%) in Terms of Value, by Type, 2021

Increasing demand of poultry industry that include ducks is expected to drive the market growth during the forecast period.

A major part of the poultry industry is constituted by ducks worldwide, which is expected to drive the market growth over the forecast period. For instance, according to an article published by ScienceDirect on September 2021, there were 33.51 million ducks as per the 20th livestock census against 23.53 million in the 19th livestock census in India which shows a change of 42.4%. This means that the demand for ducks and duck farming is increasing, mandating the need for proper surveillance and monitoring of diseases affecting ducks in order to control them.

Duck Medicine and Vaccines Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 1,777.0 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	7.7%	2028 Value Projection:	US$ 2,992.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Medicine, Vaccines By Application: Farm, Government
Companies covered:	Boehringer Ingelheim International GmbH., Ceva, YEBIO BIOENGINEERING CO., LTD., NAVETCO, Shangqiu Meilan Biological Engineering Co.,Ltd., Merck & Co., Inc., EGAVET, Bioveta, a.s., Jilin Zhengye Biological Products company limited, and Harbin Pharmaceutical Group Bio-vaccine Co. Ltd.
Growth Drivers:	Increasing demand of the poultry industry Increasing prevalence of diseases of duck Increasing research and development activities
Restraints & Challenges:	High cost involved in the treatment Limited access to the vaccines in emerging economies, such as India, Brazil, and others.

Figure 2. Global Duck Medicine and Vaccines Market Share (%), by Application, 2021

Increasing prevalence of viral and bacterial diseases of ducks is expected to drive market growth during the forecast period.

The increasing prevalence of viral and bacterial infectious diseases in ducks is expected to drive market growth during the forecast period. For instance, according to an article published by ScienceDirect in September 2021, duck diseases were underreported between 2000 and 2007, but several reports on disease prevalence showed a gradual increase from 2008 to 2015.

Global Duck Medicine and Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus pandemic has negatively impacted the development, production, and supply of medicines and the growth of the pharmaceutical businesses of various companies across the globe. The lockdown has resulted in the closure of industrial establishments, except for the manufacturing of essential commodities and there has been disruption in the supply chain of pharmaceuticals. Thus, the COVID-19 pandemic has affected the economy in three main ways: 1) by directly affecting the production and demand; 2) disrupting distribution channels; and 3) causing financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. are disrupted due to the global lockdown, while many countries, such as Saudi Arabia, the UAE, Egypt, and others, are facing problems with regard to the transportation of drugs from one place to another. Due to all these reasons, the growth of global duck medicines and vaccines market was negatively hampered.

Global Duck Medicine and Vaccines Market: Restraint

The major factors that hinder growth of the global duck medicine and vaccines market include high treatment cost and limited access to the vaccines in emerging economies, such as India, Brazil, and others.

Key Players

Major players operating in the global duck medicine and vaccines market include Boehringer Ingelheim International GmbH., Ceva, YEBIO BIOENGINEERING CO., LTD., NAVETCO, Shangqiu Meilan Biological Engineering Co.,Ltd., Merck & Co., Inc., EGAVET, Bioveta, a.s., Jilin Zhengye Biological Products company limited, and Harbin Pharmaceutical Group Bio-vaccine Co. Ltd.

Table of Content

*Browse 27 market data tables and 31 figures on "Global Duck Medicine and Vaccines Market” - forecast to 2028

Segmentation

Detailed Segmentation:

Global Duck Medicine and Vaccines Market, By Type:
- Medicine
- Vaccines
Global Duck Medicine and Vaccines Market, By Application:
- Farm
- Application
Global Duck Medicine and Vaccines Market, By Region:
- North America
  - By Type
    - Medicine
    - Vaccines
  - By Application
    - Farm
    - Government
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Type
    - Medicine
    - Vaccines
  - By Application
    - Farm
    - Government
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Type
    - Medicine
    - Vaccines
  - By Application
    - Farm
    - Government
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Type
    - Medicine
    - Vaccines
  - By Application
    - Farm
    - Government
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Type
    - Medicine
    - Vaccines
  - By Application
    - Farm
    - Government
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Type
    - Medicine
    - Vaccines
  - By Application
    - Farm
    - Government
  - By Country
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global duck medicine and vaccines market during the forecast period (2021-2028)?

The global duck medicine and vaccines market size accounted to be valued at US$ 1,777.0 million in 2021 and is expected to exhibit a CAGR of 7.7% between the forecast period (2021 and 2028)

What are the major factors driving the market growth?

Increasing demand of the poultry industry, Increasing prevalence of diseases of duck, Increasing research and development activities are the major factors driving the growth of the market.

Which is the leading application segment in the market?

Farm is the leading application segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include high treatment cost and limited access to the vaccines in emerging economies, such as India, Brazil, and others.

Which are the major players operating in the market?

Major players operating in the market include Boehringer Ingelheim International GmbH., Ceva, YEBIO BIOENGINEERING CO., LTD., NAVETCO, Shangqiu Meilan Biological Engineering Co.,Ltd., Merck & Co., Inc., EGAVET, Bioveta, a.s., Jilin Zhengye Biological Products company limited, and Harbin Pharmaceutical Group Bio-vaccine Co. Ltd.